Fundraising FoxPMV Pharma
Cranbury, US · Founded 2013 · 8 known investors
Find your way into PMV Pharma
Sign up to see every warm intro you have to PMV Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PMV Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PMV Pharma is a precision oncology company developing therapies that selectively target mutant p53 to treat cancers whose tumors carry p53 gene mutations. Its lead program is rezatapopt, a reactivator of the p53 Y220C mutation in clinical trials.
Founders & leadership
PMV Pharma was founded in 2013 by David H. Mack, Ph.D..
Board
Investors · 8
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Nextech Invest's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: Viking Global's portfolio page · Not right? Tell us
How we know: fiercebiotech.com · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$73.7M disclosed across 1 of 2 rounds · 2017–2020
- Undisclosed amountIPOSep 2020Source ↗
▶$73.7MraisedMar 2017 · 9 investors · PharmaceuticalsRule 506(b)
- David MackExecutive Officer, Director
- Peter ThompsonDirector
- Steve WinickDirector
- Arnold OronskyDirector
- Arnold LevineDirector
- Offering amount
- $73.7M
- Amount sold
- $73.7M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does PMV Pharma do?
- PMV Pharma is a precision oncology company developing therapies that selectively target mutant p53 to treat cancers whose tumors carry p53 gene mutations. Its lead program is rezatapopt, a reactivator of the p53 Y220C mutation in clinical trials.
- Who founded PMV Pharma?
- PMV Pharma was founded by David H. Mack, Ph.D. in 2013.
- Who are PMV Pharma's investors?
- PMV Pharma's investors include Avoro Capital Advisors, Nextech Invest, OUP (Osage University Partners), RA Capital, Viking Global, Wellington Management, OrbiMed.
- How much funding has PMV Pharma raised?
- PMV Pharma has disclosed $73.7M raised across 1 of its 2 known rounds.
- Where is PMV Pharma headquartered?
- PMV Pharma is headquartered in Cranbury, US.